SUBSCRIBE
SUBSCRIBE

EyePoint

NEWS
AbbVie recently returned the rights of eye drug Ab
Drug Development
EyePoint Reports Long-Term Positive Results from Phase III Yutiq Trial
EyePoint Pharmaceuticals announced positive topline 36-month follow-up data from the second Phase III trial of Yutiq (fluocinolone acetonide intravitreal implant) for treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
March 2, 2020
 · 
2 min read
 · 
Mark Terry
Load More
480 Pleasant Street Suite B300 Watertown Massachusetts 02472 US
Visit website
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
  • Featured Employer
JOBS
IN THE PRESS
Press Releases
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - August 18, 2025
August 18, 2025
 · 
2 min read
Press Releases
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 6, 2025
 · 
2 min read
Press Releases
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
August 6, 2025
 · 
14 min read
Press Releases
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
July 31, 2025
 · 
2 min read
Press Releases
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
July 30, 2025
 · 
14 min read
Press Releases
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 16, 2025
July 17, 2025
 · 
2 min read
Press Releases
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) to new employees
June 16, 2025
 · 
2 min read
Press Releases
EyePoint Announces Participation at Upcoming June 2025 Investor Conferences
May 29, 2025
 · 
2 min read
Press Releases
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 16, 2025
May 16, 2025
 · 
2 min read
Press Releases
EyePoint Announces Participation at Upcoming May 2025 Investor Conferences
May 14, 2025
 · 
2 min read
Load More